Tag Archives: LDL-C

March, 2017

November, 2016

  • 1 November

    Pfizer Discontinues Development of its Investigational PCSK9 Inhibitor

    Tuesday, November 1, 2016 – 6:30am EDT — Pfizer Inc. announced today the discontinuation of the global clinical development program for bococizumab, its investigational Proprotein Convertase Subtilisin Kexin type 9 inhibitor (PCSK9i). The totality of clinical information now available for bococizumab, taken together with the evolving treatment and market landscape for …

October, 2016

July, 2016

  • 11 July

    FDA Approves Amgen’s Single Monthly Injection for a PCSK9 Inhibitor

    THOUSAND OAKS, Calif., July 11, 2016 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha® (evolocumab) Pushtronex™ system (on-body infusor with prefilled cartridge), a new, monthly single-dose administration option.1 The Pushtronex system is a hands-free device designed to provide 420 …

April, 2016

  • 1 April

    Pfizer’s PCSK9 Inhibitor Succeeds in its Second Late-Stage Study

    NEW YORK–(BUSINESS WIRE)–Pfizer Inc. announced that the Phase 3 SPIRE-AI (AutoInjector) trial of the investigational Proprotein Convertase Subtilisin Kexin type 9 inhibitor (PCSK9i) bococizumab administered with a pre-filled pen met its co-primary endpoints: percent change from baseline in low-density lipoprotein cholesterol (LDL-C) reduction at 12 weeks compared to placebo and …